DCT and melanoma: Augmented antitumor immunity in BRAF-mutant melanoma (WM983A, WM793, SM1), upregulated expression of MHCI and melanoma antigens (gp100, MART1, TYRP1, and TYRP2), suppression of PD-L1 and M2-polarized macrophages